IS2427B - Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan - Google Patents

Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan

Info

Publication number
IS2427B
IS2427B IS6803A IS6803A IS2427B IS 2427 B IS2427 B IS 2427B IS 6803 A IS6803 A IS 6803A IS 6803 A IS6803 A IS 6803A IS 2427 B IS2427 B IS 2427B
Authority
IS
Iceland
Prior art keywords
gaboxadol
natal
distress
post
treatment
Prior art date
Application number
IS6803A
Other languages
English (en)
Other versions
IS6803A (is
Inventor
Ebert Bjarke
H°ngaard Andersen Peter
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2427(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of IS6803A publication Critical patent/IS6803A/is
Publication of IS2427B publication Critical patent/IS2427B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IS6803A 2000-11-20 2003-04-30 Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan IS2427B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en) 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (2)

Publication Number Publication Date
IS6803A IS6803A (is) 2003-04-30
IS2427B true IS2427B (is) 2008-10-15

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6803A IS2427B (is) 2000-11-20 2003-04-30 Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan

Country Status (33)

Country Link
US (2) US20040024038A1 (is)
EP (1) EP1337247B1 (is)
JP (1) JP4152186B2 (is)
KR (1) KR100865651B1 (is)
CN (1) CN1318027C (is)
AR (1) AR031473A1 (is)
AT (1) ATE336242T1 (is)
AU (2) AU2002223514B2 (is)
BG (1) BG107909A (is)
BR (1) BR0115668A (is)
CA (1) CA2429220C (is)
CY (1) CY1106209T1 (is)
CZ (1) CZ20031383A3 (is)
DE (1) DE60122368T2 (is)
DK (1) DK1337247T3 (is)
EA (1) EA007287B1 (is)
ES (1) ES2266308T3 (is)
HR (1) HRP20030404A2 (is)
HU (1) HUP0400505A3 (is)
IL (1) IL155587A0 (is)
IS (1) IS2427B (is)
ME (1) MEP6408A (is)
MX (1) MXPA03004349A (is)
NO (1) NO20032271D0 (is)
NZ (1) NZ525520A (is)
PL (1) PL361051A1 (is)
PT (1) PT1337247E (is)
SI (1) SI1337247T1 (is)
SK (1) SK7682003A3 (is)
UA (1) UA77403C2 (is)
WO (1) WO2002040009A1 (is)
YU (1) YU39003A (is)
ZA (1) ZA200303289B (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
BR0214431A (pt) * 2001-11-26 2004-11-03 Finzelberg Gmbh & Co Kg Preparação de extrato de gengibre estável, processo para produção da mesma, preparação galênica, e, uso de uma preparação de extrato de gengibre estabilizada e de uma preparação galênica
BRPI0410857A (pt) * 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06015196A (es) * 2004-06-29 2007-03-15 Lundbeck & Co As H Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
WO2008085206A2 (en) * 2006-12-29 2008-07-17 Prodea Systems, Inc. Subscription management of applications and services provided through user premises gateway devices
US20080280983A1 (en) * 2007-05-09 2008-11-13 Cenerx Biopharma Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
WO2012173634A1 (en) * 2011-06-16 2012-12-20 Solace Lifesciences, Inc. Systems and methods for balancing and maintaining the health of the human autonomic nervous system
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
NZ298567A (en) * 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
ATE284895T1 (de) * 1995-06-06 2005-01-15 Euro Celtique Sa Neuroaktive steroide der androstan- und pregnanreihe
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
ID27261A (id) * 1998-07-22 2001-03-22 Akzo Nobel Nv TURUNAN-TURUNAN ASAM α-AMINO FENIL ESTER
WO2001042190A1 (en) * 1999-12-08 2001-06-14 Warner-Lambert Company Method for the stereoselective synthesis of cyclic amino acids

Also Published As

Publication number Publication date
YU39003A (sh) 2006-05-25
CN1592616A (zh) 2005-03-09
ZA200303289B (en) 2005-07-27
CA2429220C (en) 2009-09-15
DK1337247T3 (da) 2006-12-04
DE60122368T2 (de) 2007-08-09
AU2002223514B2 (en) 2006-11-30
AU2351402A (en) 2002-05-27
EA200300594A1 (ru) 2003-10-30
NZ525520A (en) 2005-04-29
CN1318027C (zh) 2007-05-30
MXPA03004349A (es) 2003-08-19
EP1337247A1 (en) 2003-08-27
US20040024038A1 (en) 2004-02-05
KR20030065517A (ko) 2003-08-06
SK7682003A3 (en) 2003-10-07
JP2004513921A (ja) 2004-05-13
SI1337247T1 (sl) 2006-12-31
BR0115668A (pt) 2003-09-02
HRP20030404A2 (en) 2005-04-30
PT1337247E (pt) 2006-11-30
AR031473A1 (es) 2003-09-24
CY1106209T1 (el) 2011-06-08
US20090143435A1 (en) 2009-06-04
HUP0400505A2 (hu) 2004-07-28
CA2429220A1 (en) 2002-05-23
BG107909A (bg) 2004-08-31
EA007287B1 (ru) 2006-08-25
IL155587A0 (en) 2003-11-23
IS6803A (is) 2003-04-30
JP4152186B2 (ja) 2008-09-17
MEP6408A (xx) 2010-02-10
UA77403C2 (en) 2006-12-15
HK1075010A1 (en) 2005-12-02
NO20032271L (no) 2003-05-20
ATE336242T1 (de) 2006-09-15
WO2002040009A1 (en) 2002-05-23
HUP0400505A3 (en) 2008-08-28
ES2266308T3 (es) 2007-03-01
DE60122368D1 (de) 2006-09-28
NO20032271D0 (no) 2003-05-20
CZ20031383A3 (cs) 2003-08-13
PL361051A1 (en) 2004-09-20
KR100865651B1 (ko) 2008-10-29
EP1337247B1 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
IS2427B (is) Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan
IS2532B (is) Aðferð til að afsalta sjó
IS8267A (is) [1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
DE60007865D1 (de) Selbstaufrichtendes aufblasbares rettungsfloss
MXPA03007834A (es) Uso de agonistas inversos de gabaa, en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de transtornos cognitivos.
NO20025248D0 (no) Ildfast trykkbeholder
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
ZA200307102B (en) The use of enmantiomeric pure escitalopram.
IS6874A (is) 3,7-díasabísýkló[3.3.0]oktön og notkun þeirra í meðhöndlun á hjartsláttarglöpum
IL151146A0 (en) Process and device for the treatment of water, particularly for ships
DK1562985T3 (da) "Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme"
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
ITTO20020045A0 (it) Giubbotto per immersione.
WO2000064422A3 (en) Novel treatment of neurotraumatic conditions with raf inhibitor
ITTO20020044A0 (it) Giubbotto per immersione.
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
WO2003091447A3 (en) D1-1 nucleic acids, polypeptides and related methods
ZA200109993B (en) Early detection of flaviviruses using the NS1 glycorprotein.
FI20020868A0 (fi) Paineastia
DE59907828D1 (de) Elektrothermisch betätigbares Kleinventil
ES1042741Y (es) Cuerpo de valvula de gas de seguridad.
NO20042542L (no) Anvendelse av ascomycin for behandling av blefarit